Chronos, a chemical-free UV-C disinfection device for ultrasound probes, received FDA clearance. It offers health care professionals a fast, automated solution to reduce cross-contamination and improve infection prevention.
Infection Intel: Staying Ahead With Company Updates and Product Innovations
A recent development in infection prevention technology comes from Germitec, a French MedTech company specializing in high-level disinfection for ultrasound probes. Today, Germitec's device, Chronos, received FDA De Novo Clearance. It is the first chemical-free, UV-C high-level disinfection (HLD) device for ultrasound probes approved for marketing and distribution in the US.
Chronos offers health care professionals a fast, automated, and chemical-free method to disinfect ultrasound probes in about 90 seconds, reducing the risk of cross-contamination. Its UV-C technology penetrates microorganisms, disrupting their DNA, RNA, and cellular proteins, which may contribute to lowering the incidence of health care-associated infections (HAIs). Annually, HAIs affect an estimated 1.7 million patients in the US, posing a significant challenge to healthcare systems.
Chronos is designed to disinfect external and endocavitary ultrasound probes used across various medical specialties, including gynecology, urology, radiology, emergency medicine, anesthesia, and biopsy procedures. The FDA approved the device after a thorough review of the device’s ability to achieve microbial reduction across a broad range of clinically relevant microorganisms, which aligns with the requirements for high-level disinfection.
Ultrasound probes are classified as semicritical medical devices requiring high-level disinfection to prevent cross-contamination between patients. Proper disinfection is essential to reduce the risk of infections such as hepatitis B, C, and human papillomavirus. Despite disinfection protocols, studies have shown that some ultrasound probes may remain contaminated, even after chemical disinfection with wipes.
According to the press release, “Scientific data indicate that 13% of vaginal probes used with sheaths test positive for HPV even after disinfection with wipes⁵, and up to 70% of HAIs could be prevented with effective infection prevention and control measures. HAIs claim the lives of 99,000 patients annually in the US and pose a serious threat to health care safety, as reported by the CDC. These infections are linked to hygiene practices surrounding the procedure and the management and disinfection of the probes themselves.”
Chronos aims to address this issue by automating the disinfection process and removing potential errors associated with manual chemical disinfection. The device ensures consistent results by providing a standardized, automated disinfection method, making it easier for health care workers to maintain safety standards.
The FDA De Novo Clearance granted to Chronos marks a significant regulatory milestone for Germitec. The approval process evaluated the device's efficacy in achieving high-level disinfection for ultrasound probes without using chemicals. The device is now classified as a Class II medical device and is regulated under 21 CFR 880.6511.
Germitec CEO Vincent Gardès expressed optimism about the clearance. “Being granted FDA De Novo is an outstanding achievement for Germitec,” he stated. “This milestone is the result of several years of hard work by a first-class team and our partners. We are excited to introduce this groundbreaking chemical-free technology to the world's largest healthcare market. With the successful completion of the rigorous FDA De Novo process, our UV-C HLD solution offers validated microbial kill efficacy, providing healthcare facilities with a trusted option to protect their patients across all departments where ultrasound exams are performed. Additionally, this clearance paves the way for our future UV-C HLD products designed for long probes used in ENT and Cardiology departments.”
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.